Analysts expect Airsculpt Technologies to report Q2 2026 revenue of $44.14 million and earnings of $0.015 per share, with the current $4.88 stock price trading below the $6.25 average analyst target.
The primary focus for investors is same-center sales (SSC) growth and the success of the company’s ‘GLP-1 tailwind’ service offerings designed to capture demand from medical weight loss patients. This report follows a critical turning point in Q1 2026, where the company delivered its first positive same-center sales in over two years.
Management is targeting sequential improvement in both revenue and EBITDA during this seasonally stronger quarter, supported by a refreshed marketing strategy and expansion into adjacent procedures like skin excision.